Drug: infliximab, recombinant Quarter: 2016Q3
Total Records: 276 Number of Pages: 14
| DRUGNAME | PT | EventCount |
|---|---|---|
| INFLIXIMAB, RECOMBINANT | Stenotrophomonas infection | 1 |
| INFLIXIMAB, RECOMBINANT | Syndactyly | 1 |
| INFLIXIMAB, RECOMBINANT | Systemic lupus erythematosus | 1 |
| INFLIXIMAB, RECOMBINANT | Teratogenicity | 1 |
| INFLIXIMAB, RECOMBINANT | Testicular seminoma (pure) | 1 |
| INFLIXIMAB, RECOMBINANT | Thrombotic thrombocytopenic purpura | 1 |
| INFLIXIMAB, RECOMBINANT | Toxic skin eruption | 1 |
| INFLIXIMAB, RECOMBINANT | Treatment failure | 1 |
| INFLIXIMAB, RECOMBINANT | Treatment noncompliance | 1 |
| INFLIXIMAB, RECOMBINANT | Tuberculosis of central nervous system | 1 |
| INFLIXIMAB, RECOMBINANT | Type IV hypersensitivity reaction | 1 |
| INFLIXIMAB, RECOMBINANT | Upper respiratory tract infection | 1 |
| INFLIXIMAB, RECOMBINANT | Vascular malformation | 1 |
| INFLIXIMAB, RECOMBINANT | Vascular stent restenosis | 1 |
| INFLIXIMAB, RECOMBINANT | Viral infection | 1 |
| INFLIXIMAB, RECOMBINANT | Visual acuity reduced | 1 |
Total Records: 276 Number of Pages: 14